EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ROS-Responsive Fluorinated Oxalate Nanomedicine for Dual Chemiluminescence/1⁹F MRI Imaging and Targeted Drug Release

Anatoly Peshkov iD, Anel Urazaliyeva, Dariyana Saiduldinova, Kazbek Kulbergenov, Nasir Bala Alhassan iD, Almaz Beisenbayev iD, Yerkin Shabdan iD, Bauyrzhan Umbayev iD, Vsevolod Peshkov, Timur Sh Atabaev, Timur Elebessov iD, Tri Thanh Pham iD und 1 weitere

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26073304 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Anatoly Peshkov und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical and Materials Engineering, School of Engineering and Digital Sciences, Nazarbayev University, Astana 010000, Kazakhstan. Hauptthemen laut MEDLINE: Oxalates, Reactive Oxygen Species, Magnetic Resonance Imaging, Nanomedicine. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan, Nazarbayev University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this study, we developed a novel theranostic nanomedicine formulation that integrates multimodal imaging with controlled drug release in reactive oxygen species (ROS)-rich microenvironments. A fluorinated oxalate compound (FOC) was synthesized through a one-step condensation reaction between 1,1,1,3,3,3-hexafluoro-2-propanol and oxalyl chloride, characterized by 1H, 13C, and 1⁹F NMR spectroscopy. The FOC and luminophore-incorporated nanomedicine formulations reacted rapidly with hydrogen peroxide via the peroxyoxalate chemiluminescence (POCL) mechanism, producing strong chemiluminescence and inducing a notable 19-fold increase in ratiometric 1⁹F NMR signal upon conversion to fluorinated alcohol (FAH), demonstrating promising potential for high-contrast 1⁹F MRI in deep tissue. Following ROS stimulation, the chemical conversion from hydrophobic FOC to hydrophilic FAH led to the degradation of the nanomedicines, facilitating payload release. In vitro experiments with A-431 cancer cells under hypoxic conditions confirmed ROS-responsive drug release, evidenced by enhanced fluorescence from model luminophores. Additionally, doxorubicin-loaded FOC nanomedicines reduced cell viability to 32% under hypoxia while remaining non-toxic in normoxic conditions. These results indicate that FOC-based nanomedicine formulations provide a promising platform for combined chemiluminescence and 1⁹F MRI with targeted therapeutic efficacy in ROS-rich inflammatory and cancerous tissues.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OxalatesReactive Oxygen SpeciesMagnetic Resonance ImagingNanomedicineHumansDrug LiberationDoxorubicinCell Line, TumorLuminescenceCell SurvivalHalogenation

Stichwörter der Autor:innen

19F MRIbioimagingcancer therapychemiluminescencenanomedicinereactive oxygen speciessmart nanocarriertheranostics

Substanzen

OxalatesReactive Oxygen SpeciesDoxorubicin

Autor:innen und Institutionen

  • Department of Chemical and Materials Engineering, School of Engineering and Digital Sciences, Nazarbayev University, Astana 010000, Kazakhstan.
  • National Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan.
  • Department of Chemistry, School of Science and Humanities, Nazarbayev University, Astana 010000, Kazakhstan.
  • Department of Biology, School of Science and Humanities, Nazarbayev University, Astana 010000, Kazakhstan.

ORCID-Profile: Anatoly Peshkov, Nasir Bala Alhassan, Almaz Beisenbayev, Yerkin Shabdan, Bauyrzhan Umbayev, Timur Elebessov, Tri Thanh Pham, Chang-Keun Lim

Förderung

  • Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan
  • Nazarbayev University

Zitieren

APA

Peshkov, A., Urazaliyeva, A., Saiduldinova, D., Kulbergenov, K., Alhassan, N. B., Beisenbayev, A., Shabdan, Y., Umbayev, B., Peshkov, V., Atabaev, T. S., Elebessov, T., Pham, T. T., & Lim, C. K. (2025). ROS-Responsive Fluorinated Oxalate Nanomedicine for Dual Chemiluminescence/1⁹F MRI Imaging and Targeted Drug Release. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26073304

Vancouver

Peshkov A, Urazaliyeva A, Saiduldinova D, Kulbergenov K, Alhassan NB, Beisenbayev A, et al. ROS-Responsive Fluorinated Oxalate Nanomedicine for Dual Chemiluminescence/1⁹F MRI Imaging and Targeted Drug Release. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26073304

BibTeX
@article{Peshkov2025,
  author = {Peshkov, Anatoly and Urazaliyeva, Anel and Saiduldinova, Dariyana and Kulbergenov, Kazbek and Alhassan, Nasir Bala and Beisenbayev, Almaz and Shabdan, Yerkin and Umbayev, Bauyrzhan and Peshkov, Vsevolod and Atabaev, Timur Sh and Elebessov, Timur and Pham, Tri Thanh and Lim, Chang-Keun},
  title = {ROS-Responsive Fluorinated Oxalate Nanomedicine for Dual Chemiluminescence/1⁹F MRI Imaging and Targeted Drug Release},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26073304}
}
Kostenlos starten →